• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Natera Inc.

    4/23/26 4:57:03 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    DEFA14A 1 ntra-20260422xdefa14a.htm DEFA14A

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    ​

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.            )

    Filed by the Registrant  ☒

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

    ☐  Preliminary Proxy Statement

    ☐  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐  Definitive Proxy Statement

    ☒  Definitive Additional Materials

    ☐  Soliciting Material under §240.14a-12

    ​

    NATERA, INC.


    (Name of Registrant as Specified In Its Charter)


    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V94814-P48866 NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN, TEXAS 78753 NATERA, INC. 2026 Annual Meeting of Stockholders To be held virtually. Vote by Wednesday, June 10, 2026 11:59 PM Eastern Time You invested in NATERA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting of Stockholders. This is an important notice regarding the availability of proxy materials for the Natera, Inc. Annual Meeting of Stockholders to be held virtually on Thursday, June 11, 2026. Vote Virtually at the Meeting* Thursday, June 11, 2026 11:30 AM, Pacific Time Virtually at: www.virtualshareholdermeeting.com/NTRA2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to Thursday, May 28, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V94815-P48866 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. 1. To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. For Class II Nominees: 01) Rowan Chapman 02) Herm Rosenman 03) Jonathan Sheena Class I Nominee: 04) Eric H. Rubin 2. To ratify the appointment of Ernst & Young LLP as Natera, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.’s named executive officers as disclosed in the proxy statement. For 4. To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers. 1 Year 5. To approve an amendment to Natera’s 2015 Equity Incentive Plan, as amended and restated. For 6. Such other business as may properly come before the Annual Meeting or any adjournment thereof.

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    6/2/2026$260.00Outperform
    Wolfe Research
    4/14/2026Outperform
    William Blair
    1/7/2026$300.00Buy
    Citigroup
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    More analyst ratings

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Natera with a new price target

    Wolfe Research resumed coverage of Natera with a rating of Outperform and set a new price target of $260.00

    6/2/26 8:35:31 AM ET
    $NTRA
    Medical Specialities
    Health Care

    William Blair initiated coverage on Natera

    William Blair initiated coverage of Natera with a rating of Outperform

    4/14/26 8:34:48 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    6/3/26 9:05:08 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    6/3/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    6/3/26 4:40:35 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NTRA
    SEC Filings

    View All

    Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer (mCRC) development program. Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study (ClinicalTrials.gov Identifier: NCT06699836) in patients with mCRC.

    6/4/26 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. "Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board," said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. "Their deep expertise across evidence generation, clinical development, biopharma, and leading cancer research institutions will be incredibly valuable as Natera continues expanding the impact of precision diagnostics in patient care." "The oncology field is moving t

    6/3/26 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

    Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos' Phase I/II trial Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II investigational immunotherapy trial. The DOC-RM trial, which began enrollment in May, is evaluating DOC1021 (dubodencel), a first-in-clas

    5/29/26 6:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    6/1/26 4:12:54 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Natera, Inc. (0001604821) (Filer)

    5/7/26 4:10:41 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Natera Inc.

    DEFA14A - Natera, Inc. (0001604821) (Filer)

    4/23/26 4:57:03 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. "Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board," said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. "Their deep expertise across evidence generation, clinical development, biopharma, and leading cancer research institutions will be incredibly valuable as Natera continues expanding the impact of precision diagnostics in patient care." "The oncology field is moving t

    6/3/26 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Reports First Quarter 2026 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter of 2025. Processed approximately 1,013,600 tests in the first quarter of 2026, compared to approximately 855,100 tests in the first quarter of 2025, an increase of 18.5%. Women's Health generated the second highest quarter

    5/7/26 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its First Quarter Results on May 7, 2026

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2026 Financial Results Date: May 7, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/443070230 A w

    4/30/26 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat

    4/13/26 8:00:00 AM ET
    $ALLO
    $NTRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care